Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

28 Feb 2017

Abstract excerpt

The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong the lives of individuals with cancer. Inevitably, however, the treated tumors recur as resistance to these targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29152593
DOI: 10.1038/s41698-017-0007-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinomaPMID 29152593Read ↗

Personalized therapy for lung cancer: striking a moving target.Semantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Emerging application of genomics-guided therapeutics in personalized lung cancer treatmentSemantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer BiologySemantic proximity Read ↗

Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.